A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
Clinical trial NCT06280716 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06280716
- Sponsor
- Eli Lilly and Company
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-24
- Primary completion
- 2025-09-25
- Enrollment
- 301
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.